Jeremiah Metzger Lecture. Targeted cancer therapy.

摘要: I have reviewed here and elsewhere the preclinical data clinical trials which demonstrated efficacy of therapy with monoclonal antibodies that block activation receptors for growth factors (12). Herceptin is now in use. Our own antibody, C225 against EGF receptor, shows great promise, but phase III need to be completed prove its efficacy. The research efforts involved scientists academia, pharmaceutical industry, National Cancer Institute, contributions were made by many collaborators. believe it highly likely blockade factor-mediated signal transduction pathways, combination chemotherapy or radiotherapy, will enhance our ability inhibit, some cases eradicate, common epithelial human malignancies (60).